ATE554106T1 - Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung - Google Patents

Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung

Info

Publication number
ATE554106T1
ATE554106T1 AT04815434T AT04815434T ATE554106T1 AT E554106 T1 ATE554106 T1 AT E554106T1 AT 04815434 T AT04815434 T AT 04815434T AT 04815434 T AT04815434 T AT 04815434T AT E554106 T1 ATE554106 T1 AT E554106T1
Authority
AT
Austria
Prior art keywords
antibodies
hpv
subject
strains
proteins
Prior art date
Application number
AT04815434T
Other languages
English (en)
Inventor
Peter Lu
Jonathan Garman
Michael Belmares
Diaz-Sarmiento Chamorro Somoza
Johannes Schweizer
Original Assignee
Arbor Vita Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbor Vita Corp filed Critical Arbor Vita Corp
Application granted granted Critical
Publication of ATE554106T1 publication Critical patent/ATE554106T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04815434T 2003-12-23 2004-12-23 Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung ATE554106T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53237303P 2003-12-23 2003-12-23
PCT/US2004/043356 WO2005063286A1 (en) 2003-12-23 2004-12-23 Antibodies for oncogenic strains of hpv and methods of their use

Publications (1)

Publication Number Publication Date
ATE554106T1 true ATE554106T1 (de) 2012-05-15

Family

ID=34738792

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04815434T ATE554106T1 (de) 2003-12-23 2004-12-23 Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung

Country Status (7)

Country Link
US (5) US7399467B2 (de)
EP (1) EP1708745B1 (de)
JP (1) JP5030594B2 (de)
AT (1) ATE554106T1 (de)
AU (1) AU2004308964B2 (de)
CA (1) CA2551560A1 (de)
WO (1) WO2005063286A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US7312041B2 (en) * 2001-02-16 2007-12-25 Arbor Vita Corporation Methods of diagnosing cervical cancer
EP1708745B1 (de) * 2003-12-23 2012-04-18 Arbor Vita Corporation Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
CN101460636A (zh) * 2006-05-11 2009-06-17 伯克顿迪金森公司 从细胞中提取蛋白质的方法
US8865162B2 (en) * 2008-06-13 2014-10-21 Oncohealth Corp. Monoclonal antibodies against HPV proteins
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
WO2010129821A1 (en) 2009-05-07 2010-11-11 Oncohealth Corporation Identification of high grade or ≥cin2 for early stages and late stages detection, screening, and diagnosis of human papillomavirus (hpv) and hpv-associated cancers
AU2008269721B2 (en) 2007-05-31 2013-01-10 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Intradermal HPV peptide vaccination
AU2015213420B2 (en) * 2007-05-31 2017-02-16 Isa Pharmaceuticals B.V. HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
EP2468763B1 (de) 2007-05-31 2014-06-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC HPV-Epitope als Ziel für zervikale Tumoren infiltrierende T-Zellen zur Verwendung bei Impfstoffen
US7838215B2 (en) * 2007-09-25 2010-11-23 Canvir, Inc. Advanced cervical cell screening methods
US9207240B2 (en) 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
CN102498217A (zh) * 2009-04-20 2012-06-13 阿波维塔公司 Hpv的e6蛋白的特异性抗体及其应用
TWI497075B (zh) * 2009-06-11 2015-08-21 Oncohealth Corp 早期及晚期人類乳突病毒感染之偵測
US9128094B2 (en) 2010-01-08 2015-09-08 Oncohealth Corp. High throughput cell-based HPV immunoassays for diagnosis and screening of HPV-associated cancers
WO2012135666A1 (en) * 2011-04-01 2012-10-04 University Of Louisiana At Monroe Inhibitors of metastasis, methods of generating such inhibitors and their therapeutic applications
US9506939B2 (en) 2013-05-06 2016-11-29 Bio-Rad Laboratories, Inc. Stabilization of labile analytes in reference materials
EP3015863A1 (de) * 2014-10-31 2016-05-04 Mikrogen GmbH Immunologischer Test zum Nachweis von E7-Onkoproteinen in biologischen Proben
MA46354A (fr) 2016-10-03 2019-08-07 Juno Therapeutics Inc Molécules se liant spécifiquement au vph
CN111954679A (zh) 2017-10-03 2020-11-17 朱诺治疗学股份有限公司 Hpv特异性结合分子
CA3088837A1 (en) * 2018-01-24 2019-08-01 The Council Of The Queensland Institute Of Medical Research Hpv immunotherapy
TWI840351B (zh) 2018-04-05 2024-05-01 美商奇諾治療有限公司 T細胞受體及表現其之工程化細胞
CN112423783A (zh) 2018-05-30 2021-02-26 德国癌症研究中心 组合的预防性和治疗性疫苗
CN115925888B (zh) * 2022-11-26 2023-06-27 山西省中医药研究院（山西省中医院） 与人乳头瘤病毒hpv特异性结合的羊驼源纳米抗体及其应用
JP2025541197A (ja) * 2022-12-14 2025-12-18 ウスタフ、ジュニア、マート 膜タンパク質の標的化捕捉のための操作されたウイルス様粒子

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
EP0111762B1 (de) 1980-06-20 1987-11-19 Unilever Plc Verfahren und Gerät zur Durchführung spezifischer Bindungsbestimmungen
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5876922A (en) 1985-07-31 1999-03-02 Institute Pasteur Papillomavirus probe and a process for in vitro diagnosis of papillomavirus infections
FR2586428B1 (fr) * 1985-08-26 1988-11-25 Pasteur Institut Polypeptides et anticorps, caracteristiques du papillomavirus et leurs applications au diagnostic in vitro, a la prevention et/ou la lutte contre des infections a papillomavirus
WO1987005630A1 (en) 1986-03-21 1987-09-24 Institut Pasteur Determined dna sequences derived from a papillomavirus genome, their uses for in vitro diagnostic purposes and the production of antigenic compositions
US4777239A (en) 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
US5204061A (en) 1987-10-08 1993-04-20 Becton, Dickinson And Company Depositing a binder on a solid support
US5180806A (en) * 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
ATE240401T1 (de) 1989-03-21 2003-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5814460A (en) * 1990-02-14 1998-09-29 Diatide, Inc. Method for generating and screening useful peptides
DE4015044A1 (de) 1990-05-10 1991-11-14 Behringwerke Ag Seroreaktive epitope auf proteinen des menschlichen papillomavirus (hpv) 18
US5753233A (en) 1990-05-10 1998-05-19 Behring Diagnostics Gmbh Seroreactive epitopes on proteins of human papilloma-virus (HPV) 18
US5932412A (en) * 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
US5604105B1 (en) 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
FR2670797A1 (fr) 1990-12-20 1992-06-26 Pasteur Institut Sequences d'adn determinees derivees du genome du papillomavirus hpv39, application de ces sequences au diagnostic in vitro d'infection par ce papillomavirus, et a la production de composition immunogene.
PT523391E (pt) * 1991-07-13 2003-08-29 Dade Behring Marburg Gmbh Utilizacao dos peptidos derivados dos genes hpv-16 e6 e e7 para fins de diagnostico
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
US5571680A (en) 1994-01-21 1996-11-05 Beckman Instruments, Inc. Homogeneous immunoassays and enzyme based assays of analytes using capillary electrophoresis
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
JP2002515734A (ja) 1996-01-02 2002-05-28 カイロン コーポレイション 遺伝子改変された樹状細胞により媒介される免疫刺激
US5643752A (en) 1996-01-18 1997-07-01 Incyte Pharmaceuticals, Inc. Tissue inhibitor of metalloproteinases
HRP970092A2 (en) 1996-02-22 1998-04-30 Merck & Co Inc Synthetic hiv genes
EP0912607A2 (de) 1996-06-21 1999-05-06 Merck & Co., Inc. Synthetische gene anthaltetnd vakzine
EP0969862B1 (de) 1997-02-07 2006-10-18 Merck & Co., Inc. Synthetische hiv gag gene
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
CA2340174C (en) 1998-08-10 2011-01-04 Antigenics Llc Compositions of cpg and saponin adjuvants and methods thereof
AU2196200A (en) 1998-12-17 2000-07-03 Johns Hopkins University School Of Medicine, The Olfactory receptor expression libraries and methods of making and using them
DE19901008A1 (de) * 1999-01-13 2000-07-20 Deutsches Krebsforsch Peptide zur Inhibierung von HPV E6-Proteinen
WO2000043410A2 (en) 1999-01-25 2000-07-27 Yale University Novel odorant receptors in drosophila
DK1208111T3 (da) 1999-02-25 2009-02-09 Univ Columbia Gener der koder for insekt-odorantreceptorer og anvendelser deraf
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
US6242266B1 (en) 1999-04-30 2001-06-05 Agilent Technologies Inc. Preparation of biopolymer arrays
JP2003506018A (ja) 1999-07-20 2003-02-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 匂いレセプター
US6440696B1 (en) 1999-07-28 2002-08-27 New England Medical Center E6 targeted protein (E6TP1)
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
GB0018140D0 (en) * 2000-07-24 2000-09-13 Medical Res Council Screening for abnormalities
WO2002007751A1 (en) 2000-07-25 2002-01-31 Axcell Biosciences Corporation Identification and isolation of novel polypeptides having pdz domains and methods of using same
US6346416B1 (en) 2000-08-29 2002-02-12 Isis Pharmaceuticals, Inc. Antisense inhibition of HPK/GCK-like kinase expression
US8613907B2 (en) * 2000-10-12 2013-12-24 University Of Rochester Compositions that inhibit proliferation of cancer cells
US20040229298A1 (en) * 2000-11-11 2004-11-18 Lu Peter S. Methods and compositions for treating cervical cancer
US7312041B2 (en) 2001-02-16 2007-12-25 Arbor Vita Corporation Methods of diagnosing cervical cancer
ATE354662T1 (de) 2001-03-23 2007-03-15 Deutsches Krebsforsch Modifizierte hpv e6- und e7-gene und -proteine als impfstoff
WO2002077012A2 (en) * 2001-03-23 2002-10-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human papilloma virus immunoreative peptides
TWI229132B (en) * 2001-05-04 2005-03-11 King Car Food Ind Co Ltd Method and detector for identifying subtypes of human papilloma viruses
EP1443951A4 (de) 2001-08-03 2006-05-03 Arbor Vita Corp Molekulare wechselwirkungen in zellen
AU2003270548B2 (en) * 2002-09-09 2008-09-25 Arbor Vita Corporation Methods of diagnosing cervical cancer
US20050118139A1 (en) 2001-08-23 2005-06-02 Lingyi Huang Vaccine using papilloma virus e proteins delivered by viral vector
EP1708745B1 (de) 2003-12-23 2012-04-18 Arbor Vita Corporation Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung
US20130017572A1 (en) 2009-04-30 2013-01-17 Lu Peter S Codon modified polynucleotide sequences for enhanced expression in a host system

Also Published As

Publication number Publication date
AU2004308964B2 (en) 2010-09-16
WO2005063286A1 (en) 2005-07-14
AU2004308964A1 (en) 2005-07-14
US20150093742A1 (en) 2015-04-02
JP2007522108A (ja) 2007-08-09
US20120164629A1 (en) 2012-06-28
JP5030594B2 (ja) 2012-09-19
US20100209904A1 (en) 2010-08-19
US9611315B2 (en) 2017-04-04
US7399467B2 (en) 2008-07-15
US20050142541A1 (en) 2005-06-30
EP1708745A4 (de) 2007-12-19
CA2551560A1 (en) 2005-07-14
EP1708745B1 (de) 2012-04-18
US20090047660A1 (en) 2009-02-19
EP1708745A1 (de) 2006-10-11

Similar Documents

Publication Publication Date Title
ATE554106T1 (de) Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung
ATE230487T1 (de) Verfahren zur frühen diagnose von carcinomen
DE60041839D1 (de) Auto-Antikörper gegen Annexin-Proteine als Marker für Lungenkrebs
DE50204883D1 (de) Verfahren zum qualitativen und/oder quantitativen nachweis von zellen
ATE540319T1 (de) Verfahren für die bestimmung von fk506
BRPI0820885B8 (pt) "anticorpo ou fraguimento do mesmo, célula de hibridoma, polinucleotídeo, polipeptídeo compreendendoum domínio de cadeia pesada ou leve de anticorpo, método para detecção de gravidez em um animal bovino, kit e método de purificação de um antígeno principal associado à gravidez (pag)".
DE69939121D1 (de) Verfahren und materialien zum nachweis und zur messung von durch freie radikale verursachten schäden
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
DE60129239D1 (de) Kit und verfahren zur bestimmung von protein esm-1
DE60325382D1 (de) Verfahren zur diagnose von gebärmutterhalskrebs
ATE529533T1 (de) Verfahren zum nachweis von analyten in einer probe
WO2005019831B1 (en) Methods for reducing complexity of a sample using small epitope antibodies
BRPI0416270A (pt) método para detectar um analito em uma amostra, e, método e kit para detectar um anticorpo especìfico de uma amostra
ATE397215T1 (de) Entstörung von immunoassays durch substanzen, die aus den framework-regionen von antikörpern abgeleitet sind
ATE392621T1 (de) Verfahren zur quantifizierung von glykiertem protein
ATE288589T1 (de) Verfahren zur analyse von proteinen
ATE383418T1 (de) Verfahren und zusammensetzungen zur bestimmung glycierter proteine
DE60228952D1 (de) Nachweis von Legionella durch ein PCR und FRET verwendendes Verfahren
ATE408832T1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
ATE535546T1 (de) Humane monoklonale antikörper, die spezifisch an ifg-ii binden
DE602004001994D1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
ATE532796T1 (de) Immunassays zur spezifischen bestimmung von scca- isoformen
DE602005015627D1 (de) Verfahren zur messung von proinsulin und c-peptid sowie kit dafür
ATE484748T1 (de) Testverfahren zur bestimmung von analyten mittels analytanalogen